Abstract
Introduction: Gestational trophoblastic disease is a spectrum of neoplastic abnormalities arising from fetal trophoblastic tissue. The range of the diseases in this group varies from relatively benign Hydatidifom mole (complete and partial mole) to highly malignant choriocarcinoma.
Methods: We have reviewed the available literature and discussed the management and follow up based on the current understanding of the natural history, extent and the prognosis of the disease.
Key observations: Depending on the underlying pathology the disease can subside, progress or even metastasize and lead to death, if left untreated. The treatment of the disease is relatively simple and the disease is highly curable by single or multi agent chemotherapy. Appropriate and timely treatment not only saves the women from morbidity and death but also can help preserve their fertility.
Conclusions: Management of Gestational disease should ideally be done in a specialized multi-disciplinary environment and the outcome of treatment in majority of the cases is very satisfactory.
Keywords: Gestational Trophoblastic Disease, Gestational Trophoblastic Neoplasia, Management Risk Scoring in GTD, role of chemotherapy.
Reviews on Recent Clinical Trials
Title:Management of Gestational Trophoblastic Diseases-An Update
Volume: 10 Issue: 4
Author(s): Dipanwita Banerjee, Salil D. Barsode and Partha Basu
Affiliation:
Keywords: Gestational Trophoblastic Disease, Gestational Trophoblastic Neoplasia, Management Risk Scoring in GTD, role of chemotherapy.
Abstract: Introduction: Gestational trophoblastic disease is a spectrum of neoplastic abnormalities arising from fetal trophoblastic tissue. The range of the diseases in this group varies from relatively benign Hydatidifom mole (complete and partial mole) to highly malignant choriocarcinoma.
Methods: We have reviewed the available literature and discussed the management and follow up based on the current understanding of the natural history, extent and the prognosis of the disease.
Key observations: Depending on the underlying pathology the disease can subside, progress or even metastasize and lead to death, if left untreated. The treatment of the disease is relatively simple and the disease is highly curable by single or multi agent chemotherapy. Appropriate and timely treatment not only saves the women from morbidity and death but also can help preserve their fertility.
Conclusions: Management of Gestational disease should ideally be done in a specialized multi-disciplinary environment and the outcome of treatment in majority of the cases is very satisfactory.
Export Options
About this article
Cite this article as:
Banerjee Dipanwita, D. Barsode Salil and Basu Partha, Management of Gestational Trophoblastic Diseases-An Update, Reviews on Recent Clinical Trials 2015; 10 (4) . https://dx.doi.org/10.2174/1574887110666150923111731
DOI https://dx.doi.org/10.2174/1574887110666150923111731 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Comparative Proteomic Profiling of Extracellular Proteins between Normal and Gastric Cancer Cells
Current Cancer Drug Targets Angiogenesis Markers in Gynecological Tumors and Patents for Anti- Angiogenic Approach: Review
Recent Patents on Anti-Cancer Drug Discovery Unravelling the Role of Infectious Agents in the Pathogenesis of Human Autoimmunity: The Hypothesis of the Retroviral Involvement Revisited
Current Molecular Medicine Vertebrate Protein CTCF and its Multiple Roles in a Large-Scale Regulation of Genome Activity
Current Genomics Genetic Alterations in Differentiated Thyroid Cancers
Endocrine, Metabolic & Immune Disorders - Drug Targets Angiogenic and Vascular Modulation by Extracellular Matrix Cleavage Products
Current Pharmaceutical Design Emulsomes Meet S-layer Proteins: An Emerging Targeted Drug Delivery System
Current Pharmaceutical Biotechnology Methylenetetrahydrofolate Reductase (MTHFR): A Novel Target for Cancer Therapy
Current Pharmaceutical Design Iron Oxide Nanoparticles: An Insight into their Biomedical Applications
Current Medicinal Chemistry Deaza Analogs of Folic Acid as Antitumor Agents
Current Pharmaceutical Design HLA-G - From Fetal Tolerance to a Regulatory Molecule in Inflammatory Diseases
Current Immunology Reviews (Discontinued) Epigenetic Targeting of Platinum Resistant Testicular Cancer
Current Cancer Drug Targets Recent Advances in the Development of Casein Kinase 1 Inhibitors
Current Medicinal Chemistry ATP-Binding Cassette Efflux Transporters in Human Placenta
Current Pharmaceutical Biotechnology Pleiotrophin as a Possible New Target for Angiogenesis-Related Diseases and Cancer
Recent Patents on Anti-Cancer Drug Discovery Expression and Function of Organic Cation and Anion Transporters (SLC22 Family) in the CNS
Current Pharmaceutical Design Passive Targeting of Cyclophosphamide-Loaded Carbonate Apatite Nanoparticles to Liver Impedes Breast Tumor Growth in a Syngeneic Model
Current Pharmaceutical Design Trophoblast Invasion: A Possible Link Between Implantation Deficiencies and Preeclampsia
Current Women`s Health Reviews Notch-Associated MicroRNAs in Cancer
Current Drug Targets Stromal Cell-Derived Factor (SDF) 2 and the Endoplasmic Reticulum Stress Response of Trophoblast Cells in Gestational Diabetes Mellitus and <i>In vitro</i> Hyperglycaemic Condition
Current Vascular Pharmacology